June 2010

ICDD will be attending the World Pharmaceutical Congress next June, 15 – 17th in Philadelphia.
Take time to meet with Nathalie Compagnone, our CEO, who will present our new posters.
* The first one describes the performances of the Mitosafe® bioenergetic balance panel in deselecting hepatotoxicants.
* The second one describes a novel in vitro assay to select disease modifying drugs for Alzheimer’s disease using primary human cells.
We will be also pleased to invite you at the booth 7, where our technological platforms, Mitosafe® and Mitostream® will be presented.

March 2010

ICDD will be attending the SOT meeting next week (8-10 March) in Salk Lake City. Our booth number is 939.
We are looking forward to meeting you there at your convenience to present our technological platforms Mitosafe® and Mitostream®.
• The Mitosafe® platform is focused on a mechanistic analysis of mitochondrial functions
• The Mitostream® platform is a high content and phenotypic analysis of mitochondrial behavior. It aims at a better anticipation of the clinical tolerance of drugs early in the drug development process.

January 2010

You missed us in the USA, come see us in Belgium. ICDD animates a booth at the 5th annual international conference on predictive human toxicity and ADME/Tox meeting in Brussel.

January 2010

ICCD presents its high content analysis technologies at the 7th annual HCA meeting in San Francisco. Our world leading services are focused on mitochondrial behavior to predict early the clinical tolerance of products in development. Come talk to us at booth #22.

Stay in California and listen to Nathalie Compagnone who will be presenting ICDD’s views and expertise at the conference “Toxicology – An engrossing subject!” at the Salk Institute in San Diego on January 26th 2010.

June 2009

Paris, June 25 th 2009, ICDD-sas recognized for its technical innovation by French minister of Education & Research, Mrs Pecresse.

This competition is well known to be one of strongest and the most rigorous in term of project selection. This price gives ICDD-sas a label of excellence, enlightens the validity of our products and the strengths of our business model.

June 2009

ICDD-sas team was present at the world pharmaceutical Congress in Philadelphia from 9th to 11th of June 2009. On this occasion Nathalie Compagnone, CEO, presented the last updates in the performances of the Mitostream® database; the selection-deselection tool to predict clinical tolerance. Pharmaceutical and biotech companies showed a strong interest in Mitostream® and pursued discussions with our team to discuss the advantage of the Mitostream® line to respond to their specific needs.

The Drug Safety Executive Council (DSEC), represented by Eric Glazer, which points out that all the recent advances in characterizing, understanding, measuring and monitoring the biology of adverse events has come about due to the utilization of new and emerging technologies such as Mitostream®, has suggested that ICDD-sas join the collaborative technology evaluation (CTE) program.

May 28th 2009

Paris, May 28th 2009, ICDD-sas receives the award of the young innovative company from “l’Usine Nouvelle” ICDD-sas received its award in the presence of M. Novelli, French minister for the industry “in the category services to the industry”. This award recognized ICDD-sas as a provider for innovative and highly performing tools for the pharmaceutical industry.

February 2009

Christine Perrin-Julien has joined ICDD-sas with a strong background in sales management and operational marketing for 15 years in Abbott Laboratories, France. Christine has a double competence in science, with a master in biotechnology quality control, and in management with a certificate in business management from IEA, Lyon. She is responsible for corporate communication, strategic commercial planning and management of the sale forces.

June 2008

ICDD-sas is laureate of the CAP innovation 2008 awards in category “espoir création-incubation”. Nathalie Compagnone received this awards from the CCI Marseille Provence and CCI Nice Côte d’Azur. This award is focused on innovative business regarding technologies, services, and products. 50 projects were evaluated within 4 categories (Creation/incubation; Start up, Sustainable development, Product and services).

March 2008

Sophie Salvat, an immunology Ph.D. with professional experience in quality control management and a Health Business Management degree from Euromed-Marseille Business School, joins ICDD as Business Developer. Dr Salvat has a strong background in drug discovery in the pre-clinical and clinial research phases gained from a 12 years of experience in the pharmaceutical industry.